Low-dose short-term cyclosporine versus etretinate in psoriasis: Improvement of skin, nail, and joint involvement

Mahrle, G.; Schulze, Hans‐Joachim; Färber, L; Weidinger, Gottfried; Steigleder, G. K.; contributors, other multicenter

doi:10.1016/0190-9622(95)90189-2

Cited by 145 publications

(105 citation statements)

References 42 publications

Supporting

Mentioning

100

Contrasting

Unclassified

Order By: Relevance

“…The three trials 21,33,34 investigating retinoids found acitretin to be more efficacious than etretinate (RD 30%, 95 CI 6-54%) 33 and less efficacious than etanercept 25 mg twice per week (RD 22%, 95% CI À4 to 49%), 34 (Table 2). In head-to-head trials etanercept 50 mg twice weekly was less efficacious than ustekinumab 90 mg (RD 17%, 95% CI 10-24%) and ustekinumab 45 mg (RD 11%, 95% CI 3-19%), 60 and more efficacious than acitretin.…”

Section: Efficacymentioning

confidence: 99%

Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials

et al. 2014

View full text Add to dashboard Cite

Section: Efficacymentioning

confidence: 99%

Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials

et al. 2014

View full text Add to dashboard Cite

“…Systemic therapy is often required in patients with nail psoriasis when extensive skin or joint disease is present or when topical therapies, intralesional therapies and phototherapies have failed [4]. Due to the potential toxicity of many systemic agents, they would not be recommended in patients presenting solely with nail disease [37]. …”

Section: Conventional Treatment Approaches To Managing Nail Psoriasismentioning

confidence: 99%

Treatment and Management of Psoriasis with Nail Involvement: A Focus on Biologic Therapy

Langley

Daudén

2010

Dermatology

View full text Add to dashboard Cite

Nail involvement in psoriasis is typically overlooked, although it can affect up to 50% of patients with psoriasis and cause functional impact as well as psychological stress that can significantly affect quality of life. In addition, psoriatic patients with nail disease tend to have a more severe skin condition, a higher rate of unremitting and progressive arthritis and more associated anxiety and depression. Historically, the treatment of nail psoriasis has proven difficult, with most patients feeling that the treatment for their nail disease was unsatisfactory. The current management of nail psoriasis includes topical, intralesional and systemic therapies, although little clinical evidence is available on the effectiveness of conventional treatments and, consequently, no specific treatment approach has been fully supported. Biologic agents are beginning to emerge as a viable option to treat patients with both cutaneous and nail clinical manifestations of psoriasis and psoriatic arthritis. The extra disease burden that nail symptoms place on the patient can be considered indicative of a more severe form of the disease and should be taken into consideration when assessing treatment options.

show abstract

“…Nevertheless, topical agents are often prescribed in patients with limited nail involvement, and a recent paper has indeed shown nail psoriasis improvement under calcipotriol plus betamethasone dipropionate two-compound ointment [4]. Although traditional systemic agents such as methotrexate, cyclosporine and acitretin can also be relatively effective, their use is limited by a serious toxicity potential [5,6]. …”

Section: Introductionmentioning

confidence: 99%

Marked Improvement in Nail Psoriasis during Treatment with Adalimumab

Irla

Yawalkar

2009

Dermatology

View full text Add to dashboard Cite

Background: Nail involvement is known as a common finding in psoriatic patients and represents a significant impact on patients’ quality of life. The treatment of nail psoriasis is often challenging, and there is a need for new therapeutic options. Biologicals effective in the treatment of moderate to severe chronic plaque psoriasis may represent a new therapeutic modality for this disease. Adalimumab is a fully human IgG1 monoclonal antibody that binds to tumor necrosis factor α with high affinity and specificity. Observations: We report two cases of rapid improvement in nail psoriasis under adalimumab monotherapy with maintained effectiveness despite intermittent treatment as well as long remission after therapy discontinuation. Conclusion: The marked improvement of our two cases indicates that adalimumab may also help ameliorate nail psoriasis and warrants further controlled studies to establish the effectiveness and therapeutic regimes.

show abstract

Low-dose short-term cyclosporine versus etretinate in psoriasis: Improvement of skin, nail, and joint involvement

Cited by 145 publications

References 42 publications

Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials

Efficacy and safety of systemic treatments for moderate‐to‐severe psoriasis: meta‐analysis of randomized controlled trials

Treatment and Management of Psoriasis with Nail Involvement: A Focus on Biologic Therapy

Marked Improvement in Nail Psoriasis during Treatment with Adalimumab

Contact Info

Product

Resources

About